Canaccord Genuity Reiterates Buy Rating on Hims & Hers Health, Inc. (HIMS)

Market Context

Hims & Hers Health, Inc. operates in the Healthcare sector. The stock currently trades at $37.96 with a market capitalization of $8.3B. The stock has declined 29.8% over the past 52 weeks.

Analyst coverage from Canaccord Genuity provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Hims & Hers Health, Inc..

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Hims & Hers Health, Inc.

Among the 10 most recent ratings: 4 Buy, 6 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Jul 01, 2026	Canaccord Genuity	Buy	N/A
Jul 01, 2026	B of A Securities	Neutral	N/A
Jun 18, 2026	Barclays	Overweight	N/A
May 26, 2026	B of A Securities	Neutral	N/A
May 22, 2026	Truist Securities	Hold	N/A

Related Tools: Analyst Ratings Dashboard | View HIMS Stock Page